Results 41 to 50 of about 1,883,437 (383)

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

New England Journal of Medicine, 2021
Summary Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines.
C. Tan, W. Chia, B. Young, Feng Zhu, B. Lim, W. Sia, T. Thein, M. Chen, Y. Leo, D. Lye, Lin‐Fa Wang   +10 more
semanticscholar   +1 more source

COVID-19 neutralizing antibodies predict disease severity and survival

medRxiv, 2020
COVID-19 exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood.
W. Garcia-Beltran, E. Lam, M. Astudillo, Diane Yang, T. Miller, J. Feldman, B. Hauser, T. Caradonna, K. Clayton, Adam D Nitido, M. Murali, G. Alter, R. Charles, A. Dighe, J. Branda, J. Lennerz, D. Lingwood, A. Schmidt, A. Iafrate, A. Balazs   +19 more
semanticscholar   +2 more sources

ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization

Viruses, 2019
Infection with Zika virus (ZIKV) came first to public attention after it was found to be associated with congenital microcephaly during the outbreak in Brazil (2015–2016). Diagnosis of ZIKV suffers from extensive cross-reactivity with other Flaviviruses,
Sami Akhras, Marie-Luise Herrlein, Fabian Elgner, Thomas Holzhauser, Eberhard Hildt   +4 more
doaj   +1 more source

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. [PDF]

, 2017
Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and leads for the design of a vaccine that can protect human beings against various clades of Human Immunodeficiency Virus (HIV).
Ashokkumar, Manickam, Babu, Hemalatha, Buddolla, Viswanath, Chandrasekaran, Padmapriyadarsini, Cheedarla, Narayanaiah, Hanna, Luke Elizabeth, Kailasam, Nandagopal, Precilla, K Lucia, Ramanathan, VD, Sundaramurthi, Jagadish Chandrabose, Swaminathan, Soumya, Vaniambadi, S Kalyanaraman, Vijayan, KK Vidya   +12 more
core   +3 more sources

Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape?

Viruses, 2012
The immune response against some viral pathogens, in particular those causing chronic infections, is often ineffective notwithstanding a robust humoral neutralizing response.
Roberto Burioni, Laura Solforosi, Massimo Clementi, Roberta A. Diotti, Matteo Castelli, Elena Criscuolo, Nicola Clementi, Giuseppe Sautto, Mancini Nicasio   +8 more
doaj   +1 more source

Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies

Frontiers in Microbiology, 2023
COVID-19 pandemic is a global public health emergency. Despite extensive research, there are still few effective treatment options available today. Neutralizing-antibody-based treatments offer a broad range of applications, including the prevention and ...
Mingtao Liu, Hui Gan, Zhiman Liang, Li Liu, Qiwen Liu, Yiyin Mai, Huihuang Chen, Baoying Lei, Shangwei Yu, Huihui Chen, Peiyan Zheng, Baoqing Sun   +11 more
doaj   +1 more source

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas. [PDF]

, 2019
Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown.
An, Zhiqiang, Fang-Hoover, June, Freed, Daniel C, Fu, Tong-Ming, Li, Fengsheng, Pereira, Lenore, Petitt, Matthew, Tabata, Takako, Wang, Dai   +8 more
core   +1 more source

Broadly neutralizing antibodies target a haemagglutinin anchor epitope

Nature, 2021
Broadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus have the potential to provide near universal protection against influenza virus infection1.
Jenna J. Guthmiller, Julianna Han, Henry A. Utset, Lei Li, L. Lan, Carole J Henry, Christopher T. Stamper, Meagan McMahon, George O’Dell, M. Fernández-Quintero, Alec W. Freyn, F. Amanat, O. Stovicek, Lauren E. Gentles, Sara T. Richey, A. T. de la Peña, Victoria C. Rosado, H. Dugan, Nai-Ying Zheng, Micah E. Tepora, Dalia J. Bitar, Siriruk Changrob, Shirin Strohmeier, Min Huang, A. García-Sastre, K. Liedl, J. Bloom, Raffael Nachbagauer, P. Palese, F. Krammer, Lynda Coughlan, A. Ward, P. Wilson   +32 more
semanticscholar   +1 more source

Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it.

PLoS ONE, 2019
Vaccines that elicit broadly cross-neutralizing antibodies, including antibodies that target the conserved stem of hemagglutinin (HA), are being developed as a strategy for next-generation influenza vaccines that protect against influenza across multiple
Wei Wang, Russell Vassell, Hyo Sook Song, Qiong Chen, Paul W Keller, Swati Verma, Esmeralda Alvarado-Facundo, Hongquan Wan, Falko Schmeisser, Clement A Meseda, Jerry P Weir, Carol D Weiss   +11 more
doaj   +1 more source

Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays

Vaccines, 2023
Although studies have demonstrated that infections with various viruses, bacteria, and parasites can modulate the immune system, no study has investigated changes in antibodies against microbial antigens after the COVID-19 mRNA vaccination.
Hiroaki Saito, Hiroki Yoshimura, Makoto Yoshida, Yuta Tani, Moe Kawashima, Taiga Uchiyama, Tianchen Zhao, Chika Yamamoto, Yurie Kobashi, Toyoaki Sawano, Seiya Imoto, Hyeongki Park, Naotoshi Nakamura, Shingo Iwami, Yudai Kaneko, Aya Nakayama, Tatsuhiko Kodama, Masatoshi Wakui, Takeshi Kawamura, Masaharu Tsubokura   +19 more
doaj   +1 more source